206
Views
1
CrossRef citations to date
0
Altmetric
Patent Evaluations

Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal

, MBA PhD
Pages 971-976 | Published online: 06 Jul 2012
 

Abstract

Two applications each claim compounds described as selective PI3Kδ inhibitors. The first claims 2-amino-3-substituted-8-methylquinoline derivatives. The second, more substantial, application claims a broad range of cyclic amine derivatives of 6-aminopurines. These are the first patent applications from Exelixis relating to its PI3Kδ inhibitor program despite its disclosure of the biological profile of its lead inhibitor XL-499 in late 2010.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,757.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.